Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00.

Andrea Joaquin Garcia Mattia Rediti David Venet Samira Majjaj Roswitha Kammler Elisabetta Munzone Lorenzo Gianni Beat Thürlimann István Láng Marco Colleoni Sherene Loi Giuseppe Viale Meredith M Regan Laurence Buisseret Françoise Rothé Christos Sotiriou

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Our results show a differential benefit of low-dose CM therapy across different TNBC subtypes. Low-dose CM therapy could be considered as a potential immunomodulatory strategy for TNBC tumors with IM subtype in the early-disease setting.

Keyphrases

low dose
high dose
clinical trial
study protocol
squamous cell carcinoma
phase ii